Topcat spironolactone hfpef

Author: cvey

August undefined, 2024

WebIn TOPCAT, spironolactone (or placebo) were started at 15 mg/day, and increased up to a maximum of 45 mg/day. The prognostic implications related to spironolactone dose are yet to be reported. We aimed to assess the average spironolactone/placebo doses provided during the trial, overall and within high-risk subgroups (e.g. elderly, renal ... Web19. okt 2024 · Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome in which patients have signs and symptoms of HF as the result of high left ventric ... Desai AS, et al. Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. N Engl J Med 2024; 376:1690. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin ...

Efficacy and Safety of Spironolactone in HFpEF and CKD

Web1. nov 2024 · Briefly, TOPCAT was a multicenter, multinational, randomized, double-blind, placebo-controlled trial comparing spironolactone to placebo therapy in adults with symptomatic HFpEF and left ventricular EF ≥45%; patients were recruited from more than … Web4. dec 2024 · The TOPCAT trial and its design have been previously described in detail, as have its main results. 19,20 The trial was an international, multicenter, double-blinded, randomized clinical trial of the aldosterone antagonist spironolactone for patients with HFpEF, defined as symptomatic HF at the time of screening and within the preceding 12 ... github actions run curl

Evaluation and management of heart failure with preserved ejection …

Web16. nov 2024 · The design of the TOPCAT study has been described in detail previously. 10 Briefly, TOPCAT was a multi-centre, international, randomized, double blinded, placebo-controlled trial of spironolactone in adults with HFpEF recruited from over 270 clinical sites. The trial was funded by the National Heart, Lung, and Blood Institute as a contract with ... WebFDA Briefing Document Cardiovascular and Renal Drugs Advisory Committee Meeting December 16, 2024 Spironolactone for Heart Failure with Preserved Ejection Fraction … Web23. nov 2024 · The present study demonstrated that spironolactone use led to a decreased risk of composite cardiovascular events, all‐cause mortality, and heart failure … github actions run azure cli

Spironolactone in Patients With Heart Failure ... - ScienceDirect

Universimed - Medizin im Fokus

WebIn the Americas, spironolactone was clearly superior to placebo in reducing cardiovascular events. Given these data from TOPCAT, basic science evidence for the role of aldosterone … WebIt is disappointing that the TOPCAT trial found that yet another promising treatment, spironolactone, did not affect the primary outcome of cardiovascular death, HF hospitalization, or aborted cardiac arrest in patients with HFpEF. There were 2 twists, however, that were discussed in an accompa- github actions run another workflowWeb8. aug 2024 · Post-hoc, spironolactone helped participants from the Americas, but not Eastern Europe. Determining which patients with HFpEF could respond like TOPCAT's … github actions run command line

"WebIn 1,767 patients randomized to spironolactone or placebo in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial)-Americas study, we examined the incidence of WRF (doubling of … " - Topcat spironolactone hfpef

Topcat spironolactone hfpef

TOPCAT Analysis: Spironolactone Benefits HFPEF in Americas

Web9. mar 2024 · Based on the reduction in HF hospitalizations and cardiovascular death seen during spironolactone treatment of HFpEF in the subset of patients from the Americas enrolled in the TOPCAT (Treatment of Preserved Cardiac Function with an Aldosterone Antagonist Trial), MRAs are now encouraged for treatment of selected patients with … WebSimilar to other HFpEF trials, 26,27 the elderly patients included in our study were characterized – when compared to HFpEF patients aged <65 years – by the following: a higher prevalence of females (P=0.0001); the presence of comorbidities (obesity, P<0.001; hypertension, P<0.0001; CKD, P<0.0001); and a NYHA functional class of IV (P<0.

Did you know?

Web18. máj 2014 · TOPCAT randomised 3445 patients with HFPEF to receive spironolactone, a mineralocorticoid receptor antagonist, at a dose of 15-45mg per day or placebo on top of usual care. Patients were recruited from 270 medical centres in 6 countries. Web13. apr 2024 · Heart failure (HF) is known to be a major cause of both morbidity and mortality, with an estimated prevalence of 1–2% in economically developed countries [1,2,3].An estimation from 2014 suggested that 26 million people worldwide were living with HF [], and that approximately half of these patients had HF with preserved ejection …

Web11. apr 2024 · BB reduce all-cause mortality and are currently recommended in HFrEF; however, BB use has not been shown to improve mortality more than placebo in HFpEF patients >50%. 29 Similarly, a retrospective analysis of TOPCAT demonstrated, for HFpEF patients treated with MRA, BB use increased the risk of HF hospitalizations. 30 … Web26. nov 2014 · CHICAGO, IL — A new post hoc analysis of the TOPCAT trial of spironolactone in patients with heart failure with preserved ejection fraction (HFPEF) has …

Web27. jan 2024 · Mineralocorticoid receptor blocker Spironolactone in tablet form taken daily. Starting dosage will be 25 mg OD with dosage escalation to 50 mg OD within 4 weeks if kidney function at VR was > 30 mL/min/m2 and potassium < 4.5 mmol/L. Spironolactone is not approved for the treatment of HFmrEF and HFpEF. Web1. jan 2024 · With the MRA spironolactone, the TOPCAT trial in patients with HFpEF was neutral, ... American data, the FDA convened a panel in December 2024 and the members voted 8 to 4 to expand the indication for spironolactone to HFpEF. "The HF world has, in general, accepted TOPCAT as a positive trial, and many practices are already using …

Web30. mar 2024 · In contrast to HFrEF, no device-based therapy has been approved for the treatment of HFpEF. On the basis of data from TOPCAT, ... de Denus, S. et al. Spironolactone metabolites in TOPCAT - new ...

Web8. júl 2024 · Spironolactone up-titration may be limited by side effects that could be minimized at lower than target doses, but whether lower than target doses remain efficacious is unknown. In TOPCAT, spironolactone (or placebo) were started at 15 mg/day, and increased up to a maximum of 45 mg/day. github actions run locallyWeb21. feb 2024 · SGLT2-Inhibitoren (SGLT2i) gehören seit Kurzem zu den zentralen Säulen der Behandlung von Patient*innen mit Herzinsuffizienz. Initial hochpositive Studienergebnisse bei Herzinsuffizienz mit reduzierter Linksventrikelfunktion (HFrEF) haben sich rezent auch bei Herzinsuffizienz mit mild reduzierter (HFmrEF) und erhaltener Linksventrikelfunktion … github actions runner pre installed softwareWeb9. mar 2024 · TOPCAT was a multinational, double-blind, randomized, placebo-controlled, parallel-group study that investigated the effects of the mineralocorticoid receptor … fun places to shift toWeb29. mar 2024 · This study randomized patients with HFpEF and either prior hospitalization for HF or elevated NP levels (B-type NP [BNP] ≥100 pg/ml or N-terminal proBNP ≥360 … fun places to roadtrip toWeb18. nov 2013 · The TOPCAT trial showed that spironolactone is not superior to placebo in improving CV outcomes in patients with HFpEF, with higher rates of hyperkalemia and … github actions run job if file changedWeb27. apr 2024 · In the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, patients with heart failure and preserved ejection fraction were randomly assigned to... github actions run powershell commandWeb18. sep 2024 · The relationship between frailty and outcomes and the role of frailty in modulating the benefits of spironolactone were examined in a subset of 1767 TOPCAT patients. For the cohort as a whole (mean age 71.5 years, 49% female), the mean FI at baseline was 0.37 ± 0.11. Four frailty classes were defined ranging from FI < 0.3 to FI ≥ 0.5. github actions run number